JPMorgan Chase & Co. Sells 57,904 Shares of Syneos Health, Inc. (NASDAQ:SYNH)

JPMorgan Chase & Co. reduced its holdings in shares of Syneos Health, Inc. (NASDAQ:SYNHGet Rating) by 2.6% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,179,864 shares of the company’s stock after selling 57,904 shares during the quarter. JPMorgan Chase & Co. owned 2.12% of Syneos Health worth $156,251,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of SYNH. CENTRAL TRUST Co bought a new stake in shares of Syneos Health during the 1st quarter worth $44,000. Kirr Marbach & Co. LLC IN raised its position in Syneos Health by 4.8% in the first quarter. Kirr Marbach & Co. LLC IN now owns 75,189 shares of the company’s stock valued at $6,087,000 after purchasing an additional 3,432 shares during the last quarter. Vaughan Nelson Investment Management L.P. raised its position in Syneos Health by 4.0% in the first quarter. Vaughan Nelson Investment Management L.P. now owns 814,210 shares of the company’s stock valued at $65,909,000 after purchasing an additional 31,160 shares during the last quarter. Arizona State Retirement System raised its position in Syneos Health by 0.6% in the first quarter. Arizona State Retirement System now owns 28,030 shares of the company’s stock valued at $2,269,000 after purchasing an additional 178 shares during the last quarter. Finally, Versor Investments LP raised its position in Syneos Health by 458.8% in the first quarter. Versor Investments LP now owns 13,969 shares of the company’s stock valued at $1,131,000 after purchasing an additional 11,469 shares during the last quarter. 94.80% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

SYNH has been the subject of several research reports. Guggenheim downgraded Syneos Health from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 14th. UBS Group initiated coverage on Syneos Health in a research report on Wednesday, September 7th. They issued a “neutral” rating and a $68.00 target price for the company. Mizuho dropped their target price on Syneos Health from $87.00 to $66.00 and set a “buy” rating for the company in a research report on Wednesday, October 12th. Citigroup decreased their price target on Syneos Health from $55.00 to $30.00 and set a “neutral” rating for the company in a research note on Sunday, November 6th. Finally, Barclays decreased their price target on Syneos Health from $60.00 to $30.00 and set an “overweight” rating for the company in a research note on Sunday, November 6th. Seven research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Syneos Health presently has an average rating of “Hold” and an average target price of $56.90.

Syneos Health Trading Up 2.8 %

NASDAQ SYNH opened at $32.63 on Monday. The business has a 50 day simple moving average of $45.46 and a 200 day simple moving average of $60.99. Syneos Health, Inc. has a one year low of $22.89 and a one year high of $104.17. The stock has a market capitalization of $3.36 billion, a P/E ratio of 11.87 and a beta of 1.75. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.14 and a quick ratio of 1.14.

About Syneos Health

(Get Rating)

Syneos Health, Inc provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development.

Recommended Stories

Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health, Inc. (NASDAQ:SYNHGet Rating).

Institutional Ownership by Quarter for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.